BioAge Labs (BIOA) Return on Sales (2025 - 2026)
BioAge Labs (BIOA) reported Return on Sales of 0.08% for Q1 2026, up 1.0% on a YoY basis from 0.08% in Q1 2025, and down 58.77% sequentially from 0.05% in Q4 2025.
BioAge Labs (BIOA) Return on Sales (2025 - 2026) Analysis & Trends
BioAge Labs (BIOA) has 2 years of Return on Sales data on file, last reported at 0.08% in Q1 2026.
- For the quarter ending Q1 2026, Return on Sales rose 1.0% year-over-year to 0.08%; the trailing twelve-month figure through Mar 2026 stood at 0.09% (up 89.0% YoY), and the FY2025 full-year result was 0.14%, changed N/A from the prior year.
- Return on Sales fell to 0.08% in Q1 2026, from 0.05% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.05% in Q4 2025 to a low of 0.14% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 0.00% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 0.00% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -0.01% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.00% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.00% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.00% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 0.00% |
| 10 | BioAge Labs | 930.32 Mn | 930.32 Mn | -10.37 Mn | -0.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.08% |
| Dec 31, 2025 | -0.05% |
| Sep 30, 2025 | -0.14% |
| Jun 30, 2025 | -0.11% |
| Mar 31, 2025 | -0.09% |